Terminal · Institutions

Every 13F-reported equity position this quarter, with its quarter-over-quarter change — each row traces back to the SEC filing.

DAFNA Capital Management LLC 13F Holdings -- Portfolio & Top Positions (2026-03-31)

DAFNA Capital Management LLC (CIK 1389933) reported $439.6M across 81 reported positions in its SEC 13F filing for 2026-03-31. Largest positions: RVMD ($56.5M, 12.85%), XBI ($40.7M, 9.25%), STXS ($25.2M, 5.73%), DAWN ($21.0M, 4.77%), ATRC ($17.0M, 3.88%). Source: SEC Form 13F.

RankTickerCompanyValue% PortfolioSharesAction
1RVMDREVOLUTION MEDICINES INC$56.5M12.85%580,678Trimmed
2XBISPDR S&P BIOTECH ETF$40.7M9.25%318,505Trimmed
3STXSSTEREOTAXIS INC$25.2M5.73%13.7MHold
4DAWNDAY ONE BIOPHARMACEUTICALS I$21.0M4.77%978,463Trimmed
5ATRCATRICURE INC$17.0M3.88%597,431Hold
6IDYAIDEAYA BIOSCIENCES INC$15.9M3.61%476,740Trimmed
7XENEXENON PHARMACEUTICALS INC$14.6M3.32%250,772Trimmed
8CYTKCYTOKINETICS INC$14.3M3.26%217,497Trimmed
9CMPSCOMPASS PATHWAYS PLC$13.4M3.04%2.4MAdded
10NKTRNEKTAR THERAPEUTICS$11.9M2.70%165,178Added
11IBBISHARES NASDAQ BIOTECH INDX$10.5M2.39%62,095Trimmed
12RCUSARCUS BIOSCIENCES INC$9.6M2.18%443,829Added
13NBIXNEUROCRINE BIOSCIENCES INC$9.3M2.12%70,615Hold
14LRMRLARIMAR THERAPEUTICS INC$9.1M2.08%2.0MAdded
15BCAXBICARA THERAPEUTICS INC$8.4M1.91%421,733Added
16AXGNAXOGEN INC$8.3M1.88%249,960Trimmed
17BHVNBIOHAVEN LTD$7.2M1.63%845,735Trimmed
18TNDMTANDEM DIABETES CARE INC$6.8M1.55%355,208Hold
19DNLIDENALI THERAPEUTICS INC$6.1M1.39%318,500Hold
20ASNDASCENDIS PHARMA A/S$5.9M1.35%4.0MHold
21IPSCCENTURY THERAPEUTICS INC$5.5M1.25%2.4MTrimmed
22DXCMDEXCOM INC$5.4M1.23%86,279Trimmed
23KALVKALVISTA PHARMACEUTICALS INC$5.4M1.22%267,402Trimmed
24ASNDASCENDIS PHARMA A/S$5.3M1.21%23,177Trimmed
25INGNINOGEN INC$5.2M1.19%845,179Added

Source: SEC Form 13F filings · as of 2026-03-31